C&L: Lindsay steps down at Ardana

Ardana said that CEO Maureen Lindsay has resigned and is being replaced by non-executive director Huw Jones.

Onyx Pharmaceuticals announced that Hollings C. Renton, the company's chief executive officer, plans to retire next year. The company also announced the promotion of Laura A. Brege to the newly created position of executive vice president & chief operating officer and Randy A. Kelley to senior vice president of sales and marketing.

Dr. James S. Kuo was named CEO of Duska Therapeutics on Wednesday.

Quintiles Transnational has named Jay D. Norman to serve as president of its Quintiles Consulting business.

Lawrence Gyenes joined Acusphere as chief financial officer.

ArQule has named executive vice president Peter S. Lawrence to the post of chief operating officer.

Solazyme has named Troy J. Campione, Ph.D., to the position of senior vice president of business development.

Bradmer Pharmaceuticals has appointed Zafeer Ahmad, Ph.D, to the position of vice president, manufacturing operations and has accepted the resignation of Kerry M. Barnhart, Ph.D, as president and chief scientific officer.

Indigo Pharmaceuticals has named Dennis R. Cryer, MD, FAHA as its chief medical officer.

EMD Serono has added two members to its senior leadership team: Rick Russell, executive vice president of neurology, and Oscar Kashala, MD, PhD, senior medical director of oncology in clinical development.

Chiltern has named Steve Albrecht to the role of director, business operations, late phase. The company also announced the appointment of Marco Romano, MD to the role of medical director, Europe.

NPS Pharmaceuticals has named Brian O'Callaghan as senior vice president and chief commercial officer.

Emergent BioSolutions has named Denise Landry as senior vice president, quality.

Nastech Pharmaceutical Company Inc. announced today the promotion of Henry "Rick" Costantino, Ph.D., to chief scientific officer of delivery.

John Bennett has joined Celator Pharmaceuticals as the new head of business development, and Scott Jackson has joined the company as head of commercial development.  

Metabolon has named Don Rose vice president of marketing.

ADVENTRX Pharmaceuticals has appointed Mark Erwin to the new position of vice president of commercialization.

Prism Pharmaceuticals has named Maurits W. Geerlings, MD, MBA, to the position of vice president, business development.

Kirk Essenmacher, M.D., has joined Alvine Pharmaceuticals as vice president of marketing, corporate and strategic development; Henk Kocken, Ph.D., as vice president of quality and regulatory affairs; and Revati Shreeniwas, M.D., as vice president of clinical research and development.

Dr. Michael Jolley has joined CytoCore as its director of assay development.

SkyePharma has named Jeremy Scudamore as the non-executive chairman of the company.

XOMA has named CEO and President Steven Engle as chairman of the board of directors.

Imagenetix has named Dr. Thomas Van Dyke to its Medical Advisory Board.

NextBio announced that Dr. B. Michael Silber, former senior vice president and site head of preclinical R&D at Roche Pharmaceuticals, has joined the company's Scientific Advisory Board.

Jazz Pharmaceuticals has elected Nathaniel M. Zilkha to the company's board of directors.

Anaptys Biosciences has named R. Scott Greer to the company's board of directors

SCOLR Pharma announced that Jeff Reich, M.D. and Greg Weaver, CPA, M.B.A have been appointed to the company's board.

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.